Rapid Multiplexing with Opal® Research Kits Now Available on LabSat™ Platform

Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces a new rapid multiplexing application for its LabSat Research instrument.

Information


Lunaphore Technologies S.A., a Swiss medtech firm developing innovative
next-generation equipment for cancer research and tissue diagnostics,
announces a new rapid multiplexing application for its LabSat™ Research
instrument.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190523005082/en/

FFPE IF of tonsil, 6-plex + DAPI. Total staining time: 4h12 (with Opal® 7-Color Manual IHC Kit) (Pho ...

FFPE IF of tonsil, 6-plex + DAPI. Total staining time: 4h12 (with Opal® 7-Color Manual IHC Kit) (Photo: Business Wire)

Following the signature of a co-marketing agreement between Lunaphore
Technologies S.A. and Akoya Biosciences, Inc.; Lunaphore will start
providing multiplexing protocols using Akoya’s Opal® immunoassay kits
for its staining platform LabSat™ Research, Lunaphore’s first solution
to reach the market.

LabSat™ is shown to perform rapid tests on tissue samples under 2.5
hours for a 3-plex plus counterstaining with the Opal® 4-Color Manual
IHC Kit; and under 4.5 hours for a 6-plex plus counterstaining with the
Opal® 7-Color Manual IHC Kit1. These timeframes present a 3
to 4-fold time improvement compared to the current turnaround times for
Opal® 7-Color kit using manual protocols or other automation standards.
During the study conducted by both companies, comparable intensity to
other staining methods was observed, while reproducibility presented
less than 20% of variability1. Moreover, uniformity
throughout the tissue section was tested with excellent results,
obtaining a signal gradient under 10% over 1 cm of tissue1.
This opens opportunities for users to analyze images and quantify
signals using Akoya’s imaging and software tools.

These short turnaround times are achieved thanks to a novel microfluidic
tissue processor lying at the core of Lunaphore’s innovation, which
allows researchers to perform rapid cycles of optimization in order to
reach and repeat the desired multiplexed stainings, without the need to
invest in traditional workflow automation instruments.

Lunaphore’s co-founder and CTO, Diego G. Dupouy, said: ”The great
stainings obtained with our platform are the result of team effort by
Lunaphore and Akoya, as we push both of our technologies to the next
level. Our goal is to combine short turnaround times with high-quality
stainings in order to enable researchers to develop their own
immunophenotyping panels in unprecedented times.”

With the arrival of ultra-rapid automated multiplexing in LabSat™,
Lunaphore brings together state-of-the-art multiplexing techniques, the
high reproducibility of automation systems and an unmatched speed
performance, now at the reach of medium and small laboratories.

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company developing next
generation tissue autostainers. The award-winning technology based on
microfluidics is called FFeX (Fast Fluidic Exchange). It aims to perform
assays much faster than standard techniques and has demonstrated good
results in tests with cancer patient samples. Lunaphore was founded in
2014 with the vision of bringing –omics like approaches to tissue
diagnostics and has been recognized as one of the most innovative
companies nationally and internationally.

About LabSat™ Research

LabSat™ Research is a single-slide, ultra-rapid reagent delivery system
performing IHC/IF tests on tissue samples for Research Use Only. The
breakthrough speed performance of the device is achieved thanks to a
novel microfluidic tissue processor lying at the core of Lunaphore’s
innovation. This patented technology enables high precision tissue
staining, with a drastic reduction of reagent incubation times.

About IHC/IF and multiplexing

Immunohistochemistry (IHC) staining is a technique that involves the use
of antibodies to detect the presence of specific cancer biomarkers on a
tissue sample. During an IHC test, the tissue is stained with labelled
antibodies, producing a coloring on the tissue that is observable with a
bright-field microscope. This coloring or staining will signal the
presence and localization of specific cancer biomarkers within the
tissue. Immunofluorescence (IF) is a similar technique which instead
produces fluorescent stainings observable with a fluorescence
microscope. IHC and IF are among the most common tests in
immuno-oncology research to support scientists in the identification of
specific cancer types.

In order to analyze the tumor microenvironment, understanding the
spatial organization and co-expression of multiple biomarkers in a
tissue section is of key importance. With this purpose, it is possible
to stain and visualize several targets simultaneously with a technique
known as multiplexed IHC or IF. With Akoya’s Opal® fluorescent kits
-4-color and 7-color- 3 and 6 biomarkers, respectively, can be stained
at once in order to maximize the obtention of information from each
tissue section.

Disclaimer: LabSat™ Research is approved for Research Use Only and not
available for diagnostic procedures. Only marketed in Europe.

1 Data on file.